Qiagen NV (QGEN.DE)
* Singulex says entered into a strategic collaboration with Qiagen
* Qiagen submits QuantiFERON-TB Gold Plus for U.S. regulatory approval Source text for Eikon: Further company coverage:
* Qiagen enhances bioinformatics portfolio with acquisition of OmicSoft
* Says 2020 goal to advance tb detection with qft-plus clinical benefits
* Qiagen reports results for third quarter and first nine months of 2016
A federal appeals court declined Qiagen NV's bid for an emergency stay of an injunction blocking the sale of its year-old GeneReader gene-sequencing device.
* Qiagen shareholders approve return of approximately $250 million in cash to shareholders via synthetic share repurchase
* Shareholders overwhelmingly approved a proposal to return approx. $250 million in cash to shareholders through a synthetic share repurchase plan
A federal judge has ordered diagnostics technology company Qiagen NV to stop selling its new GeneReader gene-sequencing device, finding that rival Illumina Inc was likely to win a patent infringement lawsuit over the device.
* Qiagen announces plans to return approximately $250 million to shareholders via synthetic share repurchase proposal Source text for Eikon: Further company coverage: